Nkarta, Inc. (NKTX) Investment Analysis:
1. Executive Summary:
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company at the forefront of a paradigm shift in the treatment of B-cell-mediated autoimmune diseases. The company is dedicated to the discovery and development of allogeneic, "off-the-shelf" engineered natural killer (NK) cell therapies.[1, 2] Unlike the first generation of cellular immunotherapies, which relied on the complex and costly modification of a patient’s own T-cells (autologous CAR-T), Nkarta’s platform utilizes NK cells derived from healthy donors.[3, 4] This approach is designed to provide immediate availability, enhanced safety, and scalability, potentially transforming the landscape for patients suffering from severe autoimmune conditions such as lupus nephritis, systemic sclerosis, and vasculitis.[3, 5, 6]
The fundamental mechanism by which Nkarta generates value—and eventually, revenue—is the development of its lead therapeutic candidate, NKX019.[7, 8] As a clinical-stage entity, the company does not yet have approved products and does not currently generate revenue from product sales.[1, 9] Its primary economic value lies in the intellectual property and clinical data associated with its proprietary CAR-NK platform.[10, 11] Future revenue is expected to be derived from the commercialization of NKX019 and other pipeline assets, either through direct sales to healthcare providers or via strategic licensing agreements and partnerships with larger pharmaceutical organizations.[5, 6]
Core Products and Services
The centerpiece of Nkarta’s portfolio is NKX019, an allogeneic, cryopreserved, CD19-targeted CAR-NK cell therapy.[1, 3] The therapy is engineered with a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen, a biomarker found on the surface of B-cells.[2, 3] In autoimmune diseases, pathogenic B-cells are responsible for producing autoantibodies that attack healthy tissue, leading to chronic inflammation and organ damage.[1, 2] NKX019 is designed to deplete these B-cells, effectively "resetting" the immune system and allowing for long-term, drug-free remission.[2, 3]
A critical component of Nkarta’s product offering is its internal manufacturing capability.[10, 12] The company operates a state-of-the-art GMP facility in South San Francisco, which allows for the production of hundreds of doses of cell therapy from a single donor manufacturing run.[4, 12] This "off-the-shelf" model distinguishes Nkarta from autologous competitors, as it eliminates the 4–6 week manufacturing delay (the "vein-to-vein" time) associated with patient-derived therapies.[6, 10]
Primary Customer Types and End Markets
Nkarta’s primary customers will eventually include hospital systems, specialized infusion clinics, and outpatient treatment centers.[6, 13] Because NK cell therapies have a lower risk of severe side effects—such as cytokine release syndrome (CRS) and neurotoxicity—compared to T-cell therapies, they are uniquely suited for administration in the outpatient setting.[14, 15, 16] This drastically expands the potential provider base and reduces the burden on intensive care resources.[6, 17]
The company's most important end markets are patients with refractory B-cell-mediated autoimmune diseases.[3, 6] These markets are substantial and underserved, including:
* Lupus Nephritis (LN): A severe inflammation of the kidneys caused by systemic lupus erythematosus (SLE).[18, 19]
* Systemic Sclerosis (SSc): A chronic connective tissue disease characterized by skin thickening and internal organ involvement.[3, 6]
* ANCA-associated Vasculitis (AAV): A group of rare diseases causing inflammation of the small blood vessels.[3, 20]
* Generalized Myasthenia Gravis (gMG): A chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.[2, 7]
Competitive Value Proposition
Customers and payers are expected to choose Nkarta’s therapies over alternatives due to three primary factors: safety, speed, and cost.[6, 13, 15] Traditional biologics often require lifelong administration and may not achieve complete remission.[21, 22] Autologous CAR-T therapies, while effective, are prohibitively expensive (often exceeding $400,000 per dose) and logistically complex.[13, 16, 17] In contrast, Nkarta’s allogeneic NK cells are immediately available, have demonstrated a superior safety profile in early trials, and are projected to have a significantly lower cost of goods sold (COGS), enabling more favorable pricing and reimbursement dynamics.[13, 15, 23]
2. Business Drivers & Strategic Overview:
The strategic trajectory of Nkarta is defined by its pivot from oncology to the high-growth field of immunology.[5, 6] This transition, solidified in late 2024 and early 2025, reflects an understanding that the unique safety and manufacturing advantages of the CAR-NK platform are most transformative in the context of chronic autoimmune disorders.[6, 10]
Product Detail: The Engineering of NKX019
To understand what is actually being sold, one must examine the specific engineering that makes NKX019 a viable medicine.[1, 3] Nkarta starts with healthy donor natural killer cells, which are then modified using the company's proprietary platform.[4, 11] These modifications include:
| Feature |
Mechanism |
Clinical Benefit |
| CD19-Targeted CAR |
Humanized antibody fragment directed at CD19. |
Enables precise recognition and killing of pathogenic B-cells.[2, 3] |
| Membrane-bound IL-15 |
Co-expression of IL-15 cytokine on the cell surface. |
Enhances NK cell persistence and expansion in vivo without systemic toxicity.[2, 6] |
| NKSTIM Platform |
Proprietary activation and expansion cell line. |
Allows for the production of hundreds of doses from a single donor.[4, 12] |
| Cryopreservation |
Optimized freezing protocol for off-the-shelf storage. |
Enables "on-demand" delivery to treatment centers globally.[6, 12] |
NKX019 is currently being evaluated in two multi-center, open-label trials: Ntrust-1 and Ntrust-2.[3, 8] These trials utilize a "3+3" dose-escalation design to determine the optimal therapeutic dose for multiple indications.[24] Recently, the company advanced to a dose level of 12 billion cells per cycle (4 billion cells administered on days 0, 3, and 7), which is intended to maximize the depth of B-cell depletion.[3, 7] This intensification of treatment is a direct response to early clinical data suggesting that deeper depletion leads to more durable patient responses.[2, 25]
Moat Analysis: Barriers to Competition
Nkarta is building a multi-layered moat around its business, encompassing intellectual property, manufacturing scale, and regulatory positioning.[5, 10]
- Intellectual Property (IP): Nkarta’s IP portfolio is a significant strategic asset. The company holds three issued U.S. patents specifically covering the composition of matter for NKX019, with estimated expirations in 2040.[1] Furthermore, the company has at least 20 issued utility patents related to its broader NK cell engineering and expansion platform.[1] While the composition patents for the "NKSTIM" cells expired in late 2024, the process and method-of-use patents for manufacturing engineered NK cells extend as far as 2046, creating a long-term barrier for potential followers.[1]
- Manufacturing Scale and Cost Advantage: Vertical integration is a core component of Nkarta's strategy.[10] By operating its own 88,000-square-foot GMP facility, the company avoids the margin compression and scheduling bottlenecks typical of third-party CDMOs.[4, 10, 12] Nkarta projects that at peak commercial scale, the cost of manufacturing will be approximately $2,000 per dose.[23, 26, 27] This is a massive cost advantage compared to the estimated $60,000–$100,000 COGS for autologous CAR-T, allowing Nkarta to achieve superior margins or engage in more aggressive pricing to capture market share.[13]
- Regulatory Moat: By advancing NKX019 into multiple autoimmune indications, Nkarta is establishing a first-mover advantage in a complex regulatory landscape.[5, 6] The company has already harmonized its enrollment protocols and gained FDA clearance for a combined independent Data Safety Monitoring Board (iDSMB), which accelerates the trial process and sets a high bar for competitors who must navigate similar regulatory hurdles.[2, 25, 28]
- Distribution and Ecosystem Advantage: The safety profile of CAR-NK cells allows them to be administered in the community setting rather than just academic medical centers.[6, 17] Nkarta is building a network of ~45 partner centers, which could create an ecosystem advantage; once clinicians are trained on the Nkarta protocol and experience the ease of off-the-shelf dosing, the switching costs (in terms of clinical workflow and training) become a deterrent for competitors.[13]
TAM / Market Opportunity Analysis
The market opportunity for Nkarta in the autoimmune space is arguably larger and more lucrative than its original oncology targets.[6]
| Indication |
Market Projection (2028-2030) |
Unmet Need / Opportunity |
| Systemic Lupus (SLE) |
$4.26 Billion by 2030 |
Need for steroid-sparing therapies and "curative" remissions.[21, 29] |
| Lupus Nephritis (LN) |
$2.98 Billion by 2030 |
Current treatments often fail to prevent chronic kidney disease.[18, 19] |
| Systemic Sclerosis |
$2.1 Billion by 2028 |
Very few effective treatments for progressive skin and lung fibrosis.[6] |
| Myasthenia Gravis |
$3.5 Billion+ |
High burden of chronic treatment; need for rapid disease control.[7] |
The total addressable market across all B-cell-mediated autoimmune diseases is estimated to exceed $150 billion globally by 2030.[6, 30] If Nkarta can capture even 5% of this market with a curative or long-term remission therapy, the revenue potential could exceed $7.5 billion annually.[6] The company currently estimates that the specific autoimmune indications it is pursuing represent a ~$6 billion to $9 billion TAM in the near term.[13]
Competitive Landscape: Positioning and Momentum
Nkarta operates in a "red ocean" of cell therapy innovation, facing competition from both emerging biotech and established pharmaceutical giants.[5, 31]
- Fate Therapeutics (FATE): Fate is the most direct competitor in the allogeneic NK space, utilizing an iPSC-derived platform.[5] While iPSCs offer theoretical uniformity, Nkarta’s donor-derived cells are currently perceived to have a more established cytotoxic profile.[4, 10] Fate’s large pipeline makes it a major valuation driver in the public markets, but Nkarta’s focus on autoimmune indications has allowed it to differentiate its strategic momentum.[5]
- Sana Biotechnology (SANA): Sana’s "Hypoimmune" platform focuses on evading immune rejection.[5, 31] This could lead to longer cell persistence, but the technology is earlier-stage than Nkarta’s clinical programs.[31] Sana’s market cap of ~$720 million (as of mid-2025) reflects investor interest in persistence-enhancing technologies.[31]
- Autologous CAR-T (Gilead, Bristol Myers Squibb): These incumbents have established market shares in oncology.[5, 31] However, their pivot to autoimmune disease is hampered by the logistical burden of personalized manufacturing.[6, 10] Nkarta is gaining ground by offering a solution that is "door-to-dose" in less than six hours, compared to the weeks required for Gilead or BMS.[13]
- Non-Cellular Alternatives (Bispecifics/TCEs): T-cell engagers (TCEs) offer the simplicity of an "off-the-shelf" biologic.[5] While they are cheaper to manufacture, they often require continuous dosing.[5] Nkarta’s value proposition is a "one-and-done" reset, which would offer superior clinical value and cost-effectiveness over the long term.[6, 13]
Strategic analysis suggests that Nkarta is currently gaining ground in the autoimmune space due to its disciplined clinical execution and the 2025 restructuring, which successfully extended its cash runway to 2029.[6, 7, 8] The recent observation of "complete B-cell depletion" in all treated patients is a significant clinical catalyst that many competitors have yet to demonstrate consistently.[2, 25]
3. Financial Performance & Valuation:
The financial profile of Nkarta is typical of a high-growth, clinical-stage biotechnology company: characterized by significant R&D investment, a lack of current revenue, and a strong emphasis on maintaining a "fortress" balance sheet.[1, 9, 32]
Recent Historical Performance (Full Year 2025)
For the fiscal year ended December 31, 2025, Nkarta reported financial results that underscore the impact of its 2025 corporate restructuring.[3, 7, 8]
| Metric (in thousands) |
Year Ended Dec 31, 2025 |
Year Ended Dec 31, 2024 |
Variance (%) |
| Total Revenue |
$0 |
$0 |
N/A |
| R&D Expense |
$90,400 |
$108,000 (est) |
-16.3% |
| G&A Expense |
$31,600 |
$40,000 (est) |
-21.0% |
| Total Op Expenses |
$122,000 |
$148,000 (est) |
-17.6% |
| Interest Income |
$15,500 |
$19,300 |
-19.7% |
| Net Loss |
($104,100) |
($128,700) (est) |
-19.1% |
| Loss Per Share |
($1.41) |
($1.75) (est) |
-19.4% |
The reduction in operating expenses is primarily attributed to a 40% headcount reduction in May 2025 and the termination of an expensive facility lease in July 2025.[6, 7, 33] Despite the net loss, the company generated $15.5 million in interest income from its substantial investment portfolio, helping to offset its burn rate.[33]
Liquidity and Capital Resources
As of December 31, 2025, Nkarta held $295.1 million in cash, cash equivalents, and marketable securities.[3, 7] This represents a robust liquidity position that management expects will fund operations into 2029.[7, 8, 34] This extended runway is a critical valuation driver, as it ensures the company can reach pivotal clinical milestones for the Ntrust-1 and Ntrust-2 programs without the immediate need for a dilutive capital raise.[6, 7]
However, the company has remained opportunistic in its capital strategy. In March 2026, Nkarta initiated a $350 million mixed-securities shelf offering, including a $100 million at-the-market (ATM) facility.[32, 35] This provides the company with the flexibility to raise capital if clinical data triggers a significant "up-round" in the share price.[32]
Valuation Analysis and Multiples
Nkarta’s current valuation presents a significant disconnect between its clinical progress and its market capitalization.[32, 36, 37]
- Market Capitalization: Approximately $150.4 million (as of April 2026).[34, 36]
- Enterprise Value (EV): Negative (given that cash of $295.1M exceeds market cap).[32, 36]
- Price-to-Book (P/B) Ratio: 0.45x–0.50x.[32, 37, 38]
- Price-to-Cash Ratio: 0.51x.
From a valuation perspective, Nkarta is trading as a "distressed asset" or a "cash shell," despite having an active Phase 1/2 clinical program with a high probability of success.[32, 37, 39] The median P/B ratio for biotech peers is 2.2x, suggesting that Nkarta is fundamentally undervalued by the market.[37]
Financial Drivers for Valuation
The most important financial drivers for Nkarta’s valuation over the next 5 years include:
- 5-Year Sales Growth: Analysts forecast that if NKX019 is approved by 2028, revenue could ramp from $0 to over $750 million by 2031 (Year 5).[40] This is driven by the uptake in Lupus Nephritis and Systemic Sclerosis.[6, 13]
- Probability-Adjusted Revenue: Given that the drug is in Phase 1/2, a typical "Probability of Success" (PoS) for an autoimmune cell therapy is approximately 15%–20%. Applying this to the $6–9B TAM yields a risk-adjusted valuation significantly higher than the current market cap.[6, 41]
- COGS and Operating Leverage: The move to a $2,000/dose manufacturing cost at scale will allow Nkarta to achieve operating margins of 30%–40% at maturity, which is superior to the margins of traditional biologic manufacturers.[13, 23]
- Share Count Assumptions: The company currently has 71.3 million shares outstanding.[1, 42] To reach commercialization, it is assumed that the share count will increase to ~100–110 million due to additional capital raises and stock-based compensation.[1, 32]
VALUATION ASYMMETRY REMAINS EXTREME
4. Risk Assessment & Macroeconomic Considerations:
Investment in Nkarta, Inc. involves a high degree of speculative risk. As a clinical-stage biotechnology company, Nkarta is subject to the inherent uncertainties of drug development and the volatility of the capital markets.[1, 3, 32]
Company-Specific Execution Risks
The primary execution risk is the clinical failure of NKX019.[6] While early data shows complete B-cell depletion, this is a biomarker, not a clinical endpoint.[24] If the "immune reset" does not lead to a durable clinical response (e.g., if autoantibodies return or if B-cells repopulate in a pathogenic manner), the therapy will fail to achieve regulatory approval.[6]
Additionally, the company is highly dependent on its internal manufacturing facility.[9, 10] Any contamination, equipment failure, or regulatory non-compliance at the South San Francisco site could lead to a clinical hold, delaying the Ntrust trials and rapidly depleting the company’s cash reserves.[3, 9, 10]
Competitive Risks
Nkarta faces intense competition from "off-the-shelf" T-cell engagers (TCEs).[5] If a TCE like a CD19/CD3 bispecific can achieve similar B-cell depletion without the need for lymphodepletion (chemotherapy), clinicians may prefer the simpler biologic over a cell therapy infusion.[5, 31] Furthermore, established players like Bristol Myers Squibb could utilize their massive R&D budgets to develop next-generation "hypoimmune" T-cells that out-compete NK cells in terms of persistence.[5, 31]
Regulatory and Legal Risks
The FDA has not yet approved a CAR-NK therapy for any indication.[1, 3] This creates regulatory risk, as the path to approval for an allogeneic cell product is more complex than for a standard biologic.[10] The company also faces potential legal risks related to intellectual property.[1] Litigation in the cell therapy space is common, and defending against claims of patent infringement could be "costly, unpredictable, and time-consuming," potentially diverting millions of dollars from R&D.[1]
Balance Sheet and Capital Allocation Risks
Nkarta’s current cash runway depends on its ability to maintain a disciplined burn rate.[7, 8] If the company encounters clinical delays or decides to expand its pipeline into solid tumors, it will be forced to raise capital.[32, 33] If the share price remains at current depressed levels, this capital raise would be highly dilutive.[32, 35] There is also a risk that the company’s high institutional ownership (80%+) could lead to sudden selling pressure if a major fund decides to exit the position.[43, 44, 45]
Industry Structure and Macroeconomic Risks
The "biotech winter" has made it difficult for small-cap clinical companies to raise capital.[7] High interest rates have reduced the "risk appetite" of institutional investors, leading to a flight to quality and a discount on long-duration assets like Nkarta.[7, 32] Any macroeconomic shock that leads to a contraction in healthcare spending or a change in the 340B pricing program could also impact the eventual commercial success of NKX019.[21, 29]
Risk Framework
- What could go wrong? NKX019 achieves B-cell depletion, but the "reset" is only temporary, and patients relapse within 6 months.
- Early Warning Sign: Clinical trial data showing a "rise in autoantibody titers" or "return of pathogenic B-cell clones" in the first 12 weeks post-infusion.[24]
- Long-term Thesis Killer: A major safety signal (e.g., secondary malignancy or fatal infection) that leads to an indefinite clinical hold by the FDA.[1, 3]
BINARY RISK PROFILE DOMINATES
5. 5-Year Scenario Analysis:
The following scenarios analyze the potential total return for NKTX shareholders over a five-year horizon (2026–2031), assuming the successful (or unsuccessful) progression of NKX019.
High Case: "The Curative Breakthrough" (Probability: 20%)
In this scenario, NKX019 achieves unprecedented success, demonstrating permanent "immune resets" in 70% of treated patients across LN, SLE, and SSc.[6, 13] The FDA grants an Accelerated Approval in 2028 based on surrogate endpoints (B-cell depletion + PERR).[24, 34]
- Key Fundamentals: Nkarta captures 10% of the LN and SLE markets within three years of launch.[6] Internal manufacturing achieves a $2,000/dose cost, leading to massive margins.[23, 26]
- Valuation Assumptions:
- Year 5 Revenue (2031): $1.5 Billion (driven by 15,000 patients at $100k net price).[13, 40]
- Net Margin: 35% ($525M Net Income).
- Share Count: 100 Million (after $150M in non-dilutive/dilutive capital raises).[32]
- Exit Multiple: 25x P/E (reflecting a dominant platform).
- Implied Future Share Price: $131.25.
Base Case: "The Specialty Standard" (Probability: 55%)
NKX019 is approved for Lupus Nephritis and Myositis by late 2028.[3, 8] It becomes the preferred choice for late-line refractory patients due to its superior safety and "off-the-shelf" convenience.[6, 15]
- Key Fundamentals: Persistence is good (6-12 months), but some patients require repeat dosing every 2 years.[6] Nkarta captures 5% of the refractory market.[13]
- Valuation Assumptions:
- Year 5 Revenue (2031): $755 Million.[40]
- Net Margin: 20% ($151M Net Income).
- Share Count: 115 Million (assuming a larger dilution at lower share prices).
- Exit Multiple: 18x P/E.
- Implied Future Share Price: $23.63.
Low Case: "The Persistence Failure" (Probability: 25%)
NKX019 fails to show durability in the Phase 2 portion of Ntrust trials.[6] B-cells return quickly, and the "reset" is no better than existing, cheaper biologics.[5]
- Key Fundamentals: Clinical programs are halted in 2027. The company is forced to liquidate its manufacturing assets and intellectual property.[6, 10]
- Valuation Assumptions:
- Year 5 Revenue (2031): $0.
- Implied Value: Remaining cash per share.
- Implied Future Share Price: $1.25.
5-Year Scenario Summary Table
| Scenario |
Year 5 Revenue (MM) |
Net Margin / Earnings |
Valuation Multiple |
Implied Share Price |
5-Year Total Return |
Probability |
| High |
$1,500 |
35% Margin |
25x P/E |
$131.25 |
6,000% |
20% |
| Base |
$755 |
20% Margin |
18x P/E |
$23.63 |
1,000% |
55% |
| Low |
$0 |
N/A |
Cash Value |
$1.25 |
-41% |
25% |
| Weighted |
$715 |
N/A |
N/A |
$39.56 |
1,760% |
100% |
ASYMMETRIC CONVEXITY ABOUNDS
6. Qualitative Scorecard:
Rating Nkarta on a scale of 1–10 (where 10 is excellent).
- Management Alignment: 8/10. CEO Paul Hastings maintains a significant stake (~390k shares).[28, 46] Recent sales were non-discretionary and tax-related, which is a neutral signal.[46, 47]
- Revenue Quality: 1/10. Pre-revenue; currently 100% reliant on speculative binary outcomes.[1, 9]
- Market Position: 9/10. Nkarta is a clear leader in the allogeneic NK autoimmune space.[5, 10] The 2025 "complete depletion" data is a major differentiator against autologous and iPSC competitors.[2, 25]
- Growth Outlook: 9/10. The transition to autoimmune disease has effectively quintupled the addressable market compared to the original oncology focus.[6, 13]
- Financial Health: 8/10. The $295M cash balance and 2029 runway provide a massive buffer during the clinical development phase.[7, 8, 34]
- Business Viability: 6/10. Durability of the NK cells is the ultimate choke point.[6] If they don't persist long enough to achieve a deep reset, the therapy becomes a commodity.[6]
- Capital Allocation: 7/10. The 2025 restructuring was a painful but necessary decision to preserve the "crown jewel" (NKX019).[6, 7]
- Analyst Sentiment: 9/10. Consensus "Strong Buy" with price targets averaging $12, reflecting high conviction in the platform among domain experts.[37, 39, 48]
- Profitability: 1/10. Deeply unprofitable and will likely remain so until 2029.[1, 8]
- Track Record: 4/10. While the IPO was successful, the subsequent failure of the oncology programs and the massive share price decline have eroded long-term shareholder value.[37, 49]
OVERALL BLENDED SCORE: 6.2 / 10
HIGH-CONVICTION CLINICAL OPTION
7. Conclusion & Investment Thesis:
The investment thesis for Nkarta, Inc. (NKTX) is predicated on the belief that its allogeneic CAR-NK platform is the "killer app" for autoimmune disease.[6, 10] By providing an "off-the-shelf" solution that is safer than T-cells and more potent than standard biologics, Nkarta is positioned to disrupt a $150 billion market.[6, 13, 15]
Key Catalysts for 2026–2027:
1. Ntrust Initial Data (2026): Presentation of clinical data from the first cohorts of the LN and Myositis trials.[3, 7, 8]
2. Dose Escalation Completion: Confirmation of safety and efficacy at the 12 billion cell/cycle level.[3, 7]
3. Regulatory Harmonization: Potential for the FDA to grant Regenerative Medicine Advanced Therapy (RMAT) designation based on early Ntrust data.[2, 25]
While the technical risks regarding NK cell persistence and the competitive threat of T-cell engagers are significant, they appear more than accounted for in the current valuation.[5, 6] At 0.5x book value, an investor is effectively buying a cash-rich company with a "free" call option on a revolutionary immune reset therapy.[32, 37]
TRANSFORMATIVE POTENTIAL REMAINS
8. Technical Analysis, Price Action & Short-Term Outlook:
NKTX is currently trading in a persistent downtrend, with the price ($2.13) remaining below the 200-day moving average of $2.36.[50, 51] Technical indicators are neutral; the RSI (54.9) and Stochastic indicators suggest the stock is neither oversold nor overbought in the immediate term.[50] Recent volume has been average, suggesting a lack of institutional "accumulation" as the market awaits the 2026 data readouts.[36, 37] The short-term outlook is "Neutral," with the stock likely to oscillate between $1.80 and $2.50 until a major clinical catalyst occurs.[36, 50]
WAITING ON DATA
- [10-K] Nkarta, Inc. Files Annual Report - Stock Titan, https://www.stocktitan.net/sec-filings/NKTX/10-k-nkarta-inc-files-annual-report-924295def511.html
- Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights, https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-third-quarter-2025-financial-results-and-0/
- Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights, https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-fourth-quarter-and-full-year-2025-financial/
- nktx-ex991_7.htm - SEC.gov, https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/nktx-ex991_7.htm
- What is Competitive Landscape of Nkarta Company? - Matrix BCG, https://matrixbcg.com/blogs/competitors/nkartatx
- Nkarta SWOT Analysis – MatrixBCG.com, https://matrixbcg.com/products/nkartatx-swot-analysis
- Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights - Stock Titan, https://www.stocktitan.net/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2025-financial-results-tucjwez7gr9t.html
- Nkarta Reports Fourth Quarter and Full Year 2025 Financial - GlobeNewswire, https://www.globenewswire.com/news-release/2026/03/25/3262553/0/en/nkarta-reports-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights.html
- Form 10-Q for Nkarta INC filed 05/14/2025, https://ir.nkartatx.com/static-files/74dc9911-b624-4de4-b9dd-7b1ba74e8147
- How Does Nkarta Company Work? - Matrix BCG, https://matrixbcg.com/blogs/how-it-works/nkartatx
- What is Brief History of Nkarta Company? – PortersFiveForce.com, https://portersfiveforce.com/blogs/brief-history/nkartatx
- Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters, https://ir.nkartatx.com/news-releases/news-release-details/nkarta-establishes-new-combined-nk-cell-therapy-manufacturing/
- Marketing Mix Analysis of Nkarta – MatrixBCG.com, https://matrixbcg.com/products/nkartatx-marketing-mix
- Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12552347/
- Engineering natural killer cells may reshape the future of cancer immunotherapy, https://www.eurekalert.org/news-releases/1111511
- Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12861900/
- State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens - MDPI, https://www.mdpi.com/1422-0067/26/22/11224
- Lupus Nephritis Market Report - Growth And Insights 2035, https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report
- Lupus Nephritis Market 2030 - $3.2 billion Revenue Forecast | GPR - Growth Plus Reports, https://www.growthplusreports.com/report/lupus-nephritis-market/8282
- Initial data from trial of AAV therapy NKX019 expected this year - ANCA Vasculitis News, https://ancavasculitisnews.com/news/initial-data-trial-aav-therapy-nkx019-expected-year/
- Systemic Lupus Erythematosus Market | Industry Report 2030 - Grand View Research, https://www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market
- Lupus Nephritis Market to Surpass USD 1.8 Billion by 2034 | 20+ Companies and Emerging Therapies Driving Growth, analyses DelveInsight - Barchart.com, https://www.barchart.com/story/news/992706/lupus-nephritis-market-to-surpass-usd-1-8-billion-by-2034-20-companies-and-emerging-therapies-driving-growth-analyses-delveinsight
- NKarta Therapeutics' NK Cells Elicit Better Response than CAR-T Cells Alone - BioSpace, https://www.biospace.com/nkarta-therapeutics-nkt-cells-elicit-better-response-than-car-t-cells-alone
- NCT06557265 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06557265
- Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights, https://ir.nkartatx.com/node/9871/pdf
- Allogeneic Natural Killer Cells Engineered to Beat Cancer, https://www.nkartatx.com/file.cfm/75/docs/Nkarta_Corp_Presentation_Nov_2020.pdf
- Allogeneic Natural Killer Cells Engineered to Beat Cancer - Nkarta Inc., https://www.nkartatx.com/file.cfm/75/docs/Nkarta_4June2020_web.pdf
- Nkarta CEO Hastings sells $53915 in NKTX stock - Investing.com, https://www.investing.com/news/insider-trading-news/nkarta-ceo-hastings-sells-53915-in-nktx-stock-93CH-4456580
- Systemic Lupus Erythematosus Market To Reach $4.26Bn By 2030 - Grand View Research, https://www.grandviewresearch.com/press-release/global-systemic-lupus-erythematosus-sle-market
- Nkarta, Inc. Stock Price: Quote, Forecast, Splits & News (NKTX) - Perplexity, https://www.perplexity.ai/finance/NKTX?comparing=NKTX,TGTX,KPTI,ACTU,SXTC,CCCC
- What is Competitive Landscape of Sana Biotechnology Company? - Porter's Five Forces, https://portersfiveforce.com/blogs/competitors/sana
- Nkarta (NKTX) Announces $350M Mixed-Securities Shelf Offering - GuruFocus, https://www.gurufocus.com/news/8745038/nkarta-nktx-announces-350m-mixedsecurities-shelf-offering
- Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K), https://www.publicnow.com/view/803A116F50C33C963AE30C21B020628F3F16F09A
- Nkarta (NASDAQ: NKTX) reports 2025 loss and extends cash runway to 2029 - Stock Titan, https://www.stocktitan.net/sec-filings/NKTX/8-k-nkarta-inc-reports-material-event-95bbf1dc589d.html
- Nkarta, Inc. $100 Million at-the-market offering 2026-03-26 - Fundz, https://app.fundz.net/fundings/nkarta-funding-round-at-the-market-offering-7d2ff8
- Buy Nkarta, Inc. Stock – NKTX Stock Quote Today & Investment Insights - Public.com, https://public.com/stocks/nktx
- Nkarta Inc Stock Price Today | NASDAQ: NKTX Live - Investing.com, https://www.investing.com/equities/nkarta-inc
- Nkarta, Inc. Common Stock (NKTX) Stock Price Today & Analysis | Buy on Gotrade, https://www.heygotrade.com/en/us-stock/nktx
- Nkarta, Inc. (NKTX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, https://public.com/stocks/nktx/forecast-price-target
- NKTX / Nkarta, Inc. (NasdaqGS) - Forecast, Price Target, Estimates, Predictions - Fintel, https://fintel.io/sfo/us/nktx
- NKX-019 by Nkarta for Marginal Zone B-cell Lymphoma: Likelihood of Approval, https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
- NKTX SEC Filings - Nkarta, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/NKTX/
- NKTX - Nkarta, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGS), https://fintel.io/so/us/nktx
- Nkarta, Inc. Ownership Profile and Analysis -- Fintuitive, https://www.fintuitive.com/app/ownership-detail/65487U108/
- Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat, https://www.marketbeat.com/instant-alerts/nkarta-inc-nasdaqnktx-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-03-12/
- Routine tax-related insider sale disclosed by Nkarta CEO Paul Hastings - Stock Titan, https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-326e5d33d0bd.html
- www.sec.gov, https://www.sec.gov/Archives/edgar/data/1787400/000114036125014740/ny20043443x1_def14a.htm
- What is the current Price Target and Forecast for Nkarta (NKTX) - Zacks Investment Research, https://www.zacks.com/stock/research/NKTX/price-target-stock-forecast
- Nkarta (NKTX) Stock Price & Overview, https://stockanalysis.com/stocks/nktx/
- NKTX Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/nkarta-inc-technical
- Nkarta (NASDAQ:NKTX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat, https://www.marketbeat.com/instant-alerts/nkarta-nasdaqnktx-stock-price-expected-to-rise-needham-company-llc-analyst-says-2026-03-26/